PMID: 8610643Apr 1, 1996Paper

High-dose cyclophosphamide, carboplatin, and etoposide with autologous stem cell rescue in patients with breast cancer

American Journal of Clinical Oncology
M deMagalhaes-SilvermanE D Ball

Abstract

This study was designed to establish the toxicity and response rates o observed with a combination of high-dose cyclophosphamide, carboplatin, and etoposide with stem cell rescue in patients with breast carcinoma. Eligibility criteria included metastatic or locally advanced breast carcinoma ; aged < or equal to 60 years; performance status Eastern Cooperative Oncology Group (ECOG) 0-1; and creatinine clearance > or equal to 65 ml/min. Chemotherapy consisted of cyclophosphamide 25 mg/kg i.v. X 4 days, etoposide 400 mg/m(2) i.v. X 4 days, and carboplatin 375 mg/m(2) X 4 days. Bone marrow or peripheral blood stem cells were reinfused 48 h after completion of chemotherapy. Seventeen patients were treated in this study. The major toxicity was gastrointestinal (grades I and II). Fevers associated with neutropenia were observed in all the patients, but no episodes of bacteremia were documented. Hematopoietic toxicities were acceptable. No toxic deaths were observed. Six patients had chemotherapy-sensitive disease at time of transplant, nine had refractory disease, and two were untested. A response rate of 62% with 18% complete response (CR) was achieved. Two patients are free of disease at +7 and +9 months after transplantation. The c...Continue Reading

References

Jan 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K AntmanL E Schnipper
Mar 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MartínL Lenaz
Nov 1, 1991·Investigational New Drugs·L D Lewis
Nov 1, 1991·Investigational New Drugs·G FraschiniG N Hortobagyi
Jan 1, 1991·Cancer Chemotherapy and Pharmacology·K Kolarić, D Vukas
Dec 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S F WilliamsJ D Bitran
Jun 1, 1988·Cancer Treatment Reviews·R CanettaM Rozencweig
Sep 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W P PetersJ O Moore

❮ Previous
Next ❯

Citations

Feb 21, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M ClemonsA Howell
Jun 2, 2000·Cancer Investigation·R D BaynesW P Peters
Feb 14, 1998·Journal of the National Cancer Institute·J ZujewskiJ Abrams

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.